Study summary

Talazoparib plus enzalutamide helped men live about 9 months longer

TALAPRO-2 trial (talazoparib plus enzalutamide) · 805 men, phase 3 · Published July 2025, The Lancet

45.8months median survival, vs 37.0 with enzalutamide alone

What was tested

Talazoparib, a PARP inhibitor, plus enzalutamide against enzalutamide alone as first treatment for metastatic castration-resistant prostate cancer, whether or not DNA-repair genes were altered.

What they found

What it means

Supports a PARP inhibitor combination as a first choice once prostate cancer becomes castration-resistant.

Lancet, via PubMed ↗ Trial record NCT03395197 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.